2
Indication details
- Control Arm
- Placebo
- Therapeutic Indication
- Treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine
- Tumour Type
-
Endocrine Tumours
- Tumour Sub-type
- Thyroid cancer - differentiated
- Tumour Stage
- Locally advanced or metastatic
- Tumour Sub-Group
- MKI targeting VEGFR, PDGFR and Raf family kinases
- Trial Name
- DECISION
- NCT Number
- NCT00984282
- Trial Phase
- Phase III
Approval details
- FDA Approval
- FDA approval November 2013
- EMA Approval
- EMA (CHMP) April 2014 EC decision June 2014
Primary Outcome(s)
- Primary Outcome(s)
- mPFS
- Evaluated Outcome
- PFS
- Form(s)
- Form 2b
Outcome Data
- PFS Control
- 5.8 months
- PFS Gain
- 5.0 months
- PFS HR
- 0.59 (0.45-0.76)
- OS HR
- OS immature, not significant
Adjustments
- QoL Comment
-
QoL was not a prespecified endpoint
- Toxicity Comment
-
Increased toxicity
Score (after adjustments)
- Preliminary non-curative score
-
3
- Toxicity adjustment
- -1
- Non-curative score
-
2
Scorecard details
- ESMO-MCBS version
- ESMO-MCBS v1.1
- Scorecard ID
- 136
- Scorecard version
- 1
- Issue date
- 06.11.2019
- Last update
- 21.07.2023
Legend
Information about symbols, abbrevations and color codes
Red = negative
Green = positive
Grey = neutral
?
Grey + ? = neutral with pending data
- DFS
- Disease-Free Survival
- DoR
- Duration of Response
- EFS
- Event-Free Survival
- HR
- Hazard Ratio
- NEB
- No evaluable benefit
- NI
- Non-inferiority Study
- ORR
- Overall Response Rate
- OS
- Overall Surival
- pCR
- Pathological Complete Response/Remission
- PFS
- Progression-Free Survival
- QoL
- Quality of Life
- RFS
- Relapse-Free Survival
- RR
- Response Rate
QoL adjustments
Other adjustments*
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
QoL adjustments
Red = negative / deterioration
Green = positive / improvement
Other adjustments*
Red = negative / deterioration
Green = positive / improvement
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
* Other adjustments include:
- Long-term plateau in the survival curve
- Long-term plateau in the PFS curve
- Early stopping or crossover
- Only improved PFS mature data shows no OS advantage and no improved Qol.